Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.

Autor: Zhou X; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA. xiaofei.zhou@takeda.com., Vaishampayan U; Karmanos Cancer Institute, Detroit, MI, USA.; University of Michigan, Ann Arbor, MI, USA., Mahalingam D; Northwestern Medical Group, Chicago, IL, USA., Harvey RD; Emory University, Atlanta, GA, USA., Chung KY; Prisma Health Cancer Institute/ITOR, Greenville, SC, USA., Sedarati F; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Dong C; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Faller DV; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Venkatakrishnan K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; EMD Serono Research & Development Institute, Inc., MB, Billerica, USA., Gupta N; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Jazyk: angličtina
Zdroj: Investigational new drugs [Invest New Drugs] 2022 Oct; Vol. 40 (5), pp. 1042-1050. Date of Electronic Publication: 2022 Aug 06.
DOI: 10.1007/s10637-022-01286-8
Abstrakt: Pevonedistat (TAK-924/MLN4924) is an investigational small molecule inhibitor of the NEDD8-activating enzyme that has demonstrated clinical activity across solid tumors and hematological malignancies. Here we report the results of a phase 1 study evaluating the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics (PK) of pevonedistat in patients with advanced solid tumors (NCT03486314). Patients received a single 50 mg/m 2 pevonedistat dose via a 1-h infusion on Days 1 (in the absence of rifampin) and 10 (in the presence of rifampin), and daily oral dosing of rifampin 600 mg on Days 3-11. Twenty patients were enrolled and were evaluable for PK and safety. Following a single dose of pevonedistat at 50 mg/m 2 , the mean terminal half-life of pevonedistat was 5.7 and 7.4 h in the presence and in the absence of rifampin, respectively. The geometric mean AUC 0-inf of pevonedistat in the presence of rifampin was 79% of that without rifampin (90% CI: 69.2%-90.2%). The geometric mean C max of pevonedistat in the presence of rifampin was similar to that in the absence of rifampin (96.2%; 90% CI: 79.2%-117%). Coadministration of pevonedistat with rifampin, a strong metabolic enzyme inducer, did not result in clinically meaningful decreases in systemic exposures of pevonedistat. The study results support the recommendation that no pevonedistat dose adjustment is needed for patients receiving concomitant CYP3A inducers. CLINICALTRIALS.GOV IDENTIFIER: NCT03486314.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: